share_log

Aussie Vapes Granted Import License in Australia

Aussie Vapes Granted Import License in Australia

澳大利亞電子煙在澳大利亞獲得進口許可證
GlobeNewswire ·  03/08 20:00

Aussie Vapes among the first companies to be granted a TGA import license for aromatherapy vaporizer devices in Australia

澳大利亞電子煙是澳大利亞首批獲得TGA芳香療法蒸發器設備進口許可證的公司之一

TORONTO, March 08, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to announce that its wholly-owned subsidiary, Australian Vaporizers Pty Limited ("Aussie Vapes"), is among the first companies in Australia to be granted a Therapeutic Goods Administration (TGA) import license for aromatherapy vaporizer devices.

多倫多,2024年3月8日(環球新聞專線)——Lifeist Wellness Inc.(“Lifeist” 或 “公司”)(多倫多證券交易所股票代碼:LFST)(法蘭克福:M5B)(OTCMKTS:LFSWF)是一家利用科學和技術進步建立改變人類健康的突破性企業的健康科技公司,欣然宣佈,其全資子公司澳大利亞Vaporizers Paporizers TY Limited(“Aussie Vapes”)是澳大利亞首批獲得芳香療法蒸發器設備進口許可證的公司之一。

"As a leading Australian online supplier of aromatherapy products, being granted this TGA import license improves our competitive advantage even further," said Meni Morim, CEO of Lifeist. "This milestone reflects our unwavering commitment to consumer safety and the highest quality standards. Aussie Vapes has an important role to play, and we wholeheartedly support the TGA's initiatives to reduce nicotine product misuse by minors. We will continue to actively participate in this evolving conversation and anticipate contributing valuable insights that can help shape future policy."

Lifeist首席執行官梅尼·莫里姆表示:“作爲澳大利亞領先的芳香療法產品在線供應商,獲得TGA進口許可證進一步提高了我們的競爭優勢。”“這一里程碑反映了我們對消費者安全和最高質量標準的堅定承諾。Aussie Vapes可以發揮重要作用,我們全心全意地支持TGA減少未成年人濫用尼古丁產品的舉措。我們將繼續積極參與這一不斷演變的對話,並有望提供有助於制定未來政策的寶貴見解。”

The TGA is Australia's regulatory authority for therapeutic goods, which includes aromatherapy vaporizer devices. It works to protect and promote public health and safety by assessing and monitoring the quality, safety, and performance of therapeutic goods sold in Australia. The TGA recently introduced regulations to address concerns related to the misuse of nicotine vaping devices by minors, and as of March 1, 2024, began requiring a special import license for entities seeking to import such devices for sale. Aussie Vapes was granted one of the first such licenses before the deadline.

TGA是澳大利亞治療產品的監管機構,其中包括芳香療法蒸發器設備。它通過評估和監測在澳大利亞銷售的治療產品的質量、安全和性能,致力於保護和促進公共健康和安全。TGA最近出臺了法規,以解決與未成年人濫用尼古丁電子煙設備有關的擔憂,並從2024年3月1日起,開始要求尋求進口此類設備進行銷售的實體必須獲得特殊進口許可證。在截止日期之前,Aussie Vapes獲得了首批此類許可證之一。

As an established market leader in Australia, Aussie Vapes recognizes that navigating the aromatherapy vaporizer import license application process presents a complicated challenge for smaller participants in the space. TGA regulations demand meticulous attention to detail, comprehensive and current documentation, and a clear understanding of rapidly evolving new industry requirements. The regulatory framework is necessarily strict and the application process can be time consuming, requiring a substantial investment of time and resources.

作爲澳大利亞知名的市場領導者,Aussie Vapes認識到,香薰蒸發器進口許可證申請流程對於該領域的規模較小的參與者來說是一項複雜的挑戰。TGA 法規要求細緻關注細節、全面和最新的文檔,並對快速變化的新行業要求有清晰的了解。監管框架必然嚴格,申請過程可能很耗時,需要投入大量的時間和資源。

In light of those facts and with an eye toward the future, Aussie Vapes is pleased to report the formation of its new B2B subsidiary, Wholesale Vaporizers. As the new market landscape for these devices continues to evolve in Australia, Aussie Vapes will take a leading role in exploring ways to use our import license to help support smaller retailers in a fully regulatorily compliant and transparent fashion.

鑑於這些事實,展望未來,Aussie Vapes很高興地報告其新的B2B子公司Wholesale Vaporizers的成立。隨着澳大利亞這些設備的新市場格局不斷髮展,Aussie Vapes將在探索如何使用我們的進口許可證方面發揮主導作用,以完全合規和透明的方式爲小型零售商提供支持。

Aussie Vapes fully supports the TGA in their efforts to restrict and reduce the abuse of nicotine products by minors and looks forward to opportunities for comment and contribution to future policy making to further refine the mechanisms by which to best achieve those goals. We are actively engaged with industry associations as part of a strategic initiative to foster stronger relationships with regulators and actively contribute to the continued formulation of effective regulations in the future. By participating in industry associations, Aussie Vapes can be at the forefront of discussions, offering insights and expertise that contribute to the development of balanced and informed regulatory frameworks.

Aussie Vapes完全支持TGA努力限制和減少未成年人濫用尼古丁產品,並期待有機會發表評論和爲未來的政策制定做出貢獻,以進一步完善最好地實現這些目標的機制。作爲戰略計劃的一部分,我們積極與行業協會合作,以加強與監管機構的關係,併爲未來持續制定有效的監管做出積極貢獻。通過參與行業協會,Aussie Vapes可以站在討論的最前沿,提供見解和專業知識,爲制定平衡而明智的監管框架做出貢獻。

We look forward to a promising 2024 of exploring new opportunities and continuing to bring the highest standards of service and customer satisfaction to the Australian market with our relentless commitment to discerning quality at a competitive price.

我們期待着在充滿希望的2024年探索新的機遇,繼續爲澳大利亞市場帶來最高標準的服務和客戶滿意度,我們堅持不懈地致力於以具有競爭力的價格提供挑剔的質量。

The Company also reports it has amended its Consulting Agreement (the "Agreement") with Singular Narrative Management Ltd. ("Singular") for the continued provision of strategic business consulting, product development, and brand marketing services to the Company as well as other services that do not include investor relations or promotional activities (the "Services"), originally announced on June 30, 2023. The amended Agreement is effective as of February 1, 2024, and only changes the compensation payable to Singular which remains payable in securities of the Company reflecting Singular's substantial time commitment and dedication in providing the Services.

該公司還報告說,它已修訂了與Singular Narrative Management Ltd.(“Singular”)簽訂的諮詢協議(“協議”),以繼續向公司提供戰略業務諮詢、產品開發和品牌營銷服務,以及最初於2023年6月30日宣佈的其他不包括投資者關係或促銷活動(“服務”)的服務。修訂後的協議自2024年2月1日起生效,僅更改了應支付給Singular的薪酬,該薪酬仍以公司的證券形式支付,這反映了Singular在提供服務方面的大量時間投入和奉獻精神。

Pursuant to the Agreement, Lifeist shall pay a monthly fee of $40,000 to Singular for the provisions of the Services, after such services have been provided in the particular month, to be satisfied in common shares ("Shares") of the Company and common share purchase warrants ("Warrants"), with the number of (i) Shares issuable to Singular determined by dividing $30,000 by the 5-day volume-weighted average price ("VWAP") for the last five days of the month in which the services are provided and (ii) Warrants issuable to Singular determined by dividing $10,000 by such VWAP. The exercise price of the Warrants shall equal the greater of the "Market Price" (as defined in Policy 1.1 of the TSXV) on the trading day prior to the date of issuance of the Warrants and $0.05 and the Warrants expire 5 years from the date of issuance.

根據協議,在特定月份提供此類服務後,Lifeist應每月向Singular支付40,000美元的費用,用於提供服務,以公司的普通股(“股份”)和普通股購買權證(“認股權證”)來支付,向Singular發行的(i)股數量由30,000美元除以5天成交量加權平均價格(“VWAP”)確定) 在提供服務的當月的最後五天內,以及 (ii) 向Singular發行的認股權證按10,000美元除以確定這樣的 VWAP。認股權證的行使價應等於認股權證發行之日前交易日的 “市場價格”(定義見多倫多證券交易所政策1.1)和0.05美元,認股權證自發行之日起5年後到期,以較高者爲準。

The term of the amended Agreement is for an additional of 6 months and may be terminated by either party with 30-days' prior notice and is automatically renewable thereafter for additional one-month periods unless otherwise terminated by either party.

修訂後的協議期限再延長 6 個月,任何一方均可在提前 30 天通知的情況下終止,此後可自動續訂一個月,除非任何一方另行終止。

The Agreement and payment thereunder which constitutes a Shares for Services transaction under the policies of the TSXV has received the conditional acceptance of the TSXV but the issuances of securities remain subject to the final acceptance of the TSXV.

根據多倫多證券交易所的政策,該協議及其下的付款構成了股票換服務交易,已獲得多倫多證券交易所的有條件接受,但證券的發行仍取決於多倫多證券交易所的最終接受。

About Lifeist Wellness Inc.
Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards including for CannMart Labs, a BHO extraction facility producing high margin cannabis 2.0 products; Australian Vapes, one of Australia's largest online retailers of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company developing and selling innovative therapies for cellular health. Information on Lifeist and its businesses can be accessed through the links below:

關於 Lifeist Wellness
Lifeist處於疫情後健康革命的最前沿,利用科學和技術的進步來建立突破性公司,改變人類健康。投資組合業務部門包括:CannMart,該公司經營B2B批發分銷業務,促進向加拿大省政府控制委員會銷售休閒大麻,包括生產高利潤大麻2.0產品的BHO提取設施CannMart Labs;澳大利亞最大的蒸發器和配件在線零售商之一澳大利亞Vapes;以及開發和銷售細胞健康創新療法的生物科學和消費者健康公司Mikra。可以通過以下鏈接訪問有關Lifeist及其業務的信息:






Contacts
Meni Morim, Lifeist Wellness Inc., CEO
Ph: 647-362-0390
Email: ir@lifeist.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Forward Looking Information
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.






聯繫人
Lifeist Wellness Inc. 首席執行官梅尼·莫里姆
Ph:647-362-0390
電子郵件: ir@lifeist.com
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任,也未以任何方式批准或不贊成本新聞稿的內容。

前瞻性信息
本新聞稿包含適用證券法所指的 “前瞻性信息”。此處包含的所有非歷史陳述均包含前瞻性信息。前瞻性信息可以通過諸如 “可能”、“期望”、“可能”、“應該”、“計劃”、“預期”、“打算”、“潛在”、“提議”、“估計”、“相信” 或否定詞語等詞語或短語來識別,或其他類似的詞語、表達方式和語法變體,或某些事件或條件 “可能” 或 “將” 發生的陳述。

The forward-looking information contained herein, including, without limitation, statements related to the expected benefits of having received a TGA import licence and the anticipated benefits its new B2B subsidiary, Wholesale Vaporizers expects to realize in the new Australian market landscape, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, expectations that the market in Australia for aromatherapy vaporizer devices will continue to develop and grow as expected, and that Wholesale Vaporizers will be able to leverage the TGA Import licence with smaller retailers, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: the failure of the market in Australia for aromatherapy vaporizer devices to grow as expected and the inadequate uptake by consumers to purchase such as anticipated and in a timely manner, if at all, and risks relating to the Company's ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company's current MD&A filed under the Company's SEDAR profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

此處包含的前瞻性信息,包括但不限於與獲得TGA進口許可證的預期收益以及其新的B2B子公司Wholesale Vaporizers預計在新的澳大利亞市場格局中實現的預期收益有關的陳述,均在本新聞發佈之日作出,基於管理層在發表此類聲明時認爲合理的假設,包括但不限於對澳大利亞芳香療法蒸發器設備市場的預期會繼續按預期發展和增長,批發蒸發器將能夠利用小型零售商的TGA進口許可證,以及其他被認爲適合具體情況的考慮因素。儘管根據管理層目前獲得的信息,我們認爲這些假設是合理的,但無法保證此類預期會被證明是正確的。就其性質而言,前瞻性信息受固有的風險和不確定性的影響,這些風險和不確定性可能是一般性的,也可能是具體的,這些風險和不確定性可能導致預期、預測、預測、預測或結論不準確,假設可能不正確,目標、戰略目標和優先事項無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的,可能導致實際業績與本新聞稿中的前瞻性信息存在重大差異。這些因素包括但不限於:澳大利亞芳香療法蒸發器設備市場未能按預期增長,消費者對按預期和及時購買(如果有的話)的接受度不足,以及與公司執行業務戰略的能力及其帶來的收益相關的風險。其他風險因素還可以在公司SEDAR簡介下提交的公司當前的MD&A中找到,網址爲 。提醒讀者不要過分依賴前瞻性信息。除非適用法律要求,否則公司沒有義務更新或修改任何前瞻性信息,無論是由於新信息、未來事件還是其他原因。本警示聲明明確限制了本新聞稿中包含的前瞻性陳述。

Source: Lifeist Wellness Inc.

資料來源:Lifeist Wellness


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論